SMLR · As filed with the SEC

Semler Scientific cash flow statement, by fiscal year

The statement as Semler Scientific presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Statements of Cash Flows · USD

USDFY2024
Year ended Dec 31, 2024
FY2023
Year ended Dec 31, 2023
FY2022
Year ended Dec 31, 2022
FY2021
Year ended Dec 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income———17,222,000
Net income40,899,00020,583,00014,325,000—
Reconciliation of Net Income to Net Cash Provided by Operating Activities:
Depreciation579,000599,000589,000628,000
Deferred tax expense (income)5,727,000(664,000)(351,000)408,000
Loss on disposal of assets for lease298,000369,000463,000362,000
Write off of prepaid software licenses—2,476,000——
Gain on short-term investments—(151,000)(77,000)—
Loss on disposal of inventory———1,202,000
Allowance for credit losses(88,000)268,000103,00063,000
Change in fair value of notes held for investment(128,000)307,000——
Change in fair value of digital assets(24,933,000)———
Stock-based compensation862,000944,000741,000749,000
Impairment of long-term investments—337,000——
Changes in Operating Assets and Liabilities:
Trade accounts receivable1,844,000(2,508,000)(367,000)(874,000)
Inventory88,00024,00081,000(1,412,000)
Prepaid expenses and other current assets(865,000)(603,000)2,576,000(2,657,000)
Other non-current assets85,00096,000(2,510,000)86,000
Accounts payable(262,000)(433,000)392,000(234,000)
Accrued expenses671,000(246,000)1,310,000638,000
Other current and non-current liabilities(367,000)(68,000)188,000(125,000)
Net Cash Provided by Operating Activities24,410,00021,330,00017,463,00016,056,000
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment(51,000)(345,000)(476,000)(318,000)
Notes receivable—(1,000,000)——
Proceeds from maturities of short-term investments—78,093,000——
Purchase of notes held for investment(500,000)—(4,679,000)—
Purchase of digital assets(189,700,000)———
Purchase of short-term investments—(57,869,000)(19,996,000)—
Purchase of assets for lease—(483,000)(1,684,000)(507,000)
Proceeds from sale (purchase) of assets for lease269,000———
Net Cash (Used in) Provided by Investing Activities(189,982,000)18,396,000(26,835,000)(825,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock119,602,000———
Taxes paid related to net settlement of equity awards(874,000)(3,510,000)(114,000)(45,000)
Common stock warrants acquired—(1,949,000)——
Treasury stock acquired——(4,991,000)—
Stock issuance expenses(3,000,000)———
Proceeds from exercise of stock options1,464,00051,000168,00058,000
Net Cash Provided by (Used in) Financing Activities117,192,000(5,408,000)(4,937,000)13,000
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(48,380,000)34,318,000(14,309,000)15,244,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD57,332,00023,014,00037,323,00022,079,000
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD8,952,00057,332,00023,014,00037,323,000
Supplemental Disclosure of Cash Flow Information:
Cash paid for taxes2,260,0004,060,0002,400,0002,647,000
Exercised put option of 211,928 common stock in SYNAPS Dx for 40,922 common stock of the company———(2,230,000)

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.